How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum

The bradykinesia and other motor signs of Parkinson's disease (PD) are linked to progressive loss of substantia nigra dopamine (DA) neurons innervating the striatum. However, the emergence of idiopathic PD is likely preceded by a prolonged subclinical phase, which may be masked by a variety of pre‐ and postsynaptic compensatory mechanisms. It is often considered self‐evident that the signs of PD manifest only when nigrostriatal degeneration has proceeded to such an extent that putative compensatory mechanisms fail to accommodate the depletion of striatal DA levels. However, the precise nature of the compensatory mechanisms, and the reason for their ultimate failure, has been elusive. In a recent computational study we modeled the effects of progressive denervation, including changes in the dynamics of interstitial DA and also adaptive or compensatory changes in postsynaptic responsiveness to DA signaling in the course of progressive nigrostriatal degeneration. In particular, we found that failure of DA signaling can occur by different mechanisms at different disease stages. We review these results and discuss their relevance for clinical and translational research, and we draw a number of predictions from our model that might be tested in preclinical experiments. © 2016 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

[1]  A. Grace,et al.  Aversive Stimuli Alter Ventral Tegmental Area Dopamine Neuron Activity via a Common Action in the Ventral Hippocampus , 2011, The Journal of Neuroscience.

[2]  Habib Zaidi,et al.  PET versus SPECT: strengths, limitations and challenges , 2008, Nuclear medicine communications.

[3]  Kirsten A. Porter-Stransky,et al.  Development of behavioral preferences for the optimal choice following unexpected reward omission is mediated by a reduction of D2‐like receptor tone in the nucleus accumbens , 2013, The European journal of neuroscience.

[4]  Erwan Bezard,et al.  Presymptomatic compensation in Parkinson's disease is not dopamine-mediated , 2003, Trends in Neurosciences.

[5]  C. Adler,et al.  Disease duration and the integrity of the nigrostriatal system in Parkinson's disease. , 2013, Brain : a journal of neurology.

[6]  P. Garris,et al.  ‘Passive stabilization’ of striatal extracellular dopamine across the lesion spectrum encompassing the presymptomatic phase of Parkinson's disease: a voltammetric study in the 6‐OHDA‐lesioned rat , 2003, Journal of neurochemistry.

[7]  P. Garris,et al.  Real‐time decoding of dopamine concentration changes in the caudate–putamen during tonic and phasic firing , 2004, Journal of neurochemistry.

[8]  O. Hikosaka Basal Ganglia Mechanisms of Reward‐Oriented Eye Movement , 2007, Annals of the New York Academy of Sciences.

[9]  H. Nijhout,et al.  Passive and active stabilization of dopamine in the striatum , 2009 .

[10]  Jakob K. Dreyer,et al.  Mathematical model of dopamine autoreceptors and uptake inhibitors and their influence on tonic and phasic dopamine signaling. , 2013, Journal of neurophysiology.

[11]  F. Fujiyama,et al.  Single Nigrostriatal Dopaminergic Neurons Form Widely Spread and Highly Dense Axonal Arborizations in the Neostriatum , 2009, The Journal of Neuroscience.

[12]  M. Kassiou,et al.  Developing a preclinical model of Parkinson's disease: A study of behaviour in rats with graded 6-OHDA lesions , 2006, Behavioural Brain Research.

[13]  P. Garris,et al.  Functional reorganization of the presynaptic dopaminergic terminal in parkinsonism , 2011, Neuroscience.

[14]  Sylvia M. L. Cox,et al.  Striatal D1 and D2 signaling differentially predict learning from positive and negative outcomes , 2015, NeuroImage.

[15]  T. Robinson,et al.  Relationship between asymmetries in striatal dopamine release and the direction of amphetamine‐induced rotation during. The first week following a unilateral 6‐OHDA lesion of the substantia nigra , 1994, Synapse.

[16]  Nan Luo,et al.  Progression of Parkinson's disease as evaluated by Hoehn and Yahr stage transition times , 2010, Movement disorders : official journal of the Movement Disorder Society.

[17]  J. Dreyer Three Mechanisms by which Striatal Denervation Causes Breakdown of Dopamine Signaling , 2014, The Journal of Neuroscience.

[18]  T. Padel,et al.  A partial lesion model of Parkinson's disease in mice – Characterization of a 6-OHDA-induced medial forebrain bundle lesion , 2015, Behavioural Brain Research.

[19]  S. Kish,et al.  Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. , 1988, The New England journal of medicine.

[20]  Rafael Luján,et al.  Disruption of Dopamine Neuron Activity Pattern Regulation through Selective Expression of a Human KCNN3 Mutation , 2013, Neuron.

[21]  P. Greengard,et al.  Regulation of the phosphorylation of the dopamine- and cAMP-regulated phosphoprotein of 32 kDa in vivo by dopamine D1, dopamine D2, and adenosine A2A receptors. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[22]  U. Ungerstedt,et al.  Quantitative recording of rotational behavior in rats after 6-hydroxy-dopamine lesions of the nigrostriatal dopamine system. , 1970, Brain research.

[23]  A. Grace,et al.  Afferent modulation of dopamine neuron firing differentially regulates tonic and phasic dopamine transmission , 2003, Nature Neuroscience.

[24]  D. Surmeier,et al.  D1 and D2 dopamine-receptor modulation of striatal glutamatergic signaling in striatal medium spiny neurons , 2007, Trends in Neurosciences.

[25]  S. Dunnett,et al.  Unilateral nigrostriatal 6-hydroxydopamine lesions in mice I: Motor impairments identify extent of dopamine depletion at three different lesion sites , 2012, Behavioural Brain Research.

[26]  Rune W. Berg,et al.  Influence of Phasic and Tonic Dopamine Release on Receptor Activation , 2010, The Journal of Neuroscience.

[27]  Terry Kenakin,et al.  New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2 , 2013, British journal of pharmacology.

[28]  D. Sulzer,et al.  How Addictive Drugs Disrupt Presynaptic Dopamine Neurotransmission , 2011, Neuron.

[29]  A. Grace,et al.  The control of firing pattern in nigral dopamine neurons: single spike firing , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[30]  David P. Daberkow,et al.  Methamphetamine neurotoxicity decreases phasic, but not tonic, dopaminergic signaling in the rat striatum , 2011, Journal of neurochemistry.

[31]  A. Grace,et al.  The control of firing pattern in nigral dopamine neurons: burst firing , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[32]  S. Lewis,et al.  Modern therapeutic approaches in Parkinson's disease , 2003, Expert Reviews in Molecular Medicine.

[33]  P. Garris,et al.  Phasic‐like stimulation of the medial forebrain bundle augments striatal gene expression despite methamphetamine‐induced partial dopamine denervation , 2013, Journal of neurochemistry.

[34]  P. Christophersen,et al.  Pharmacological modulation of the gating properties of small conductance Ca2+-activated K+ channels alters the firing pattern of dopamine neurons in vivo. , 2010, Journal of neurophysiology.

[35]  V. Lovic,et al.  Functionally Distinct Dopamine Signals in Nucleus Accumbens Core and Shell in the Freely Moving Rat , 2016, The Journal of Neuroscience.

[36]  E. Castañeda,et al.  Amphetamine-evoked rotation requires newly synthesized dopamine at 14 days but not 1 day after intranigral 6-OHDA and is consistently dissociated from sensorimotor behavior , 2009, Behavioural Brain Research.

[37]  C. Gerfen Molecular effects of dopamine on striatal-projection pathways , 2000, Trends in Neurosciences.

[38]  Anatol C. Kreitzer,et al.  Regulation of parkinsonian motor behaviours by optogenetic control of basal ganglia circuitry , 2010, Nature.

[39]  J. Obeso,et al.  How does Parkinson's disease begin? The role of compensatory mechanisms , 2004, Trends in Neurosciences.

[40]  C. Gerfen,et al.  D1 Dopamine Receptor Supersensitivity in the Dopamine-Depleted Striatum Animal Model of Parkinson’s Disease , 2003, The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry.

[41]  I. Liste,et al.  Time course of striatal changes induced by 6-hydroxydopamine lesion of the nigrostriatal pathway, as studied by combined evaluation of rotational behaviour and striatal Fos expression , 1996, Experimental Brain Research.

[42]  Richard Wade-Martins,et al.  Deficits in dopaminergic transmission precede neuron loss and dysfunction in a new Parkinson model , 2013, Proceedings of the National Academy of Sciences.

[43]  L. Regeur,et al.  Imaging of dopamine transporters and D2 receptors in patients with Parkinson’s disease and multiple system atrophy , 2004, European Journal of Nuclear Medicine and Molecular Imaging.

[44]  E. Pothos,et al.  Presynaptic Recording of Quanta from Midbrain Dopamine Neurons and Modulation of the Quantal Size , 1998, The Journal of Neuroscience.

[45]  J. Girault,et al.  Opposing Patterns of Signaling Activation in Dopamine D1 and D2 Receptor-Expressing Striatal Neurons in Response to Cocaine and Haloperidol , 2008, The Journal of Neuroscience.

[46]  H. Bergman,et al.  Redundant dopaminergic activity may enable compensatory axonal sprouting in Parkinson disease , 2014, Neurology.

[47]  G. Turrigiano Homeostatic signaling: the positive side of negative feedback , 2007, Current Opinion in Neurobiology.